Showing results (311-320 of 424) with videos related to
Sort By:
Pageof 43
JHEP Reports : Innovation in Hepatology|August 11, 2020
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN studyJamie O'Hara, Alan Finnegan, Harpal Dhillon, et al.Journal of Hepatology|October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directionsVlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.Journal of Hepatology|November 20, 2012
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized studyThierry Poynard, Jordi Bruix, Eugene R Schiff, et al.Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.Hepatology (Baltimore, Md.)|March 12, 2022
Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosisLin Lei, Alix Bruneau, Haquima El Mourabit, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 31, 2007
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trialLaetitia Fartoux, Françoise Degos, Christian Trépo, et al.Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.Journal of Hepatology|April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BStefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.Pageof 43